Friday, January 30, 2009

Icahn vs. Amlyn Pharma: Round One

Activist investor Carl Icahn is readying for a proxy battle with the management of Amylin Pharmaceuticals (AMLN-$11.03), the drugmaker best known for its diabetic treatment Byetta. The move raises questions about whether Icahn plans to push Amylin for a management shakeup or position the company for a sale. What’s Icahn’s interest in Amylin? Read More….

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.

No comments: